Mainz Biomed NV (NASDAQ:QUCY) Short Interest Update

Mainz Biomed NV (NASDAQ:QUCY) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totaling 10,530,990 shares, an increase of 996.3% from the April 30th total of 960,587 shares. Approximately 79.6% of the shares of the stock are sold short. Based on an average trading volume of 79,673,861 shares, the days-to-cover ratio is presently 0.1 days.

Mainz Biomed Stock Performance

Shares of QUCY stock traded up $0.02 on Thursday, hitting $2.95. 2,762,499 shares of the company’s stock were exchanged, compared to its average volume of 10,766,772. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93. The company has a market capitalization of $43.25 million, a PE ratio of -0.06 and a beta of 0.42. The stock’s 50 day moving average is $1.04.

Mainz Biomed (NASDAQ:QUCY) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $0.13 million during the quarter.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on QUCY. Maxim Group downgraded Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce”.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.